Clomiphene citrate is indicated for the treatment of ovulatory dysfunction in women desiring pregnancy. Impediments to achieving pregnancy must be excluded or adequately treated before beginning clomiphene citrate therapy. Those patients most likely to achieve success with clomiphene therapy include patients with polycystic ovary syndrome, amenorrhea-galactorrhea syndrome, psychogenic amenorrhea, post-oral-contraceptive amenorrhea, and certain cases of secondary amenorrhea of undetermined etiology.
Treatment of the selected patient should begin with a low dose, 50 mg daily (1 tablet) for 5 days. The dose should be increased only in those patients who do not ovulate in response to cyclic 50 mg clomiphene citrate. Please click here for full Prescribing Information and Patient Information.
Studies report that between 70% and 80% of women with ovulatory disorders will ovulate successfully with clomiphene citrate treatment, typically within the first three cycles. The pregnancy rate per cycle is approximately 10-12%.
Careful attention should be given to the selection of candidates for clomiphene citrate therapy. Pelvic examination is necessary prior to clomiphene citrate treatment and before each subsequent course. Click here for contraindications and warnings.
MiloPhene should not be used in patients with:
Please click here for full Prescribing Information and Patient Information.
